Former Fortis Life Sciences CEO and private equity executive to drive expansion into clinical end markets and accelerate strategic biopharma collaborations
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, announced the appointment of Brian Kim as Chief Executive Officer. With over two decades of experience in the life sciences industry, he brings a unique combination of scientific innovation and strategic business development to the company. His experience in driving organizational transformation and large-scale commercial growth, coupled with his deep knowledge of the life sciences sector, signifies Mission Bio’s commitment to expanding into clinical applications with biopharma partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240104537195/en/
Pictured: Brian Kim, Mission Bio CEO (Photo: Business Wire)
Brian's track record is a testament to his ability to create innovative customer solutions for clinical end markets and build valuable, high-growth companies. As Chief Executive Officer of Fortis Life Sciences, he founded and grew the company into a leading business-to-business provider of proprietary reagents for clinical customers. As Managing Director of the Biosearch Technologies division of LGC, a UK-based private equity-backed life sciences tools company, Brian spearheaded the expansion into diagnostics and therapeutic end markets, resulting in the successful sale of the company in 2020. As President of PerkinElmer’s Life Science and Tools division, he revitalized product innovation, revamped the commercial organization, and returned the business to growth.
"Brian's experience in life sciences tools commercialization and clinical end markets fits exactly with Mission Bio's vision to advance single-cell multiomics into translational research and clinical applications,” said Stuart Essig, PhD, chairman of the board at Mission Bio. “He comes at an exciting stage in the company’s evolution when our technology is beginning to make measurable progress in helping improve patient health outcomes.”
"As I step into my new role, my first objective is to support the amazing team and the growing body of customer applications built around the Tapestri platform,” said Brian. “I am committed to the founding vision of establishing Mission Bio as an essential part of the new standard for personalized medicine and targeted therapies."
About Mission Bio
Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomic analysis. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit missionbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240104537195/en/
Contacts
Consort Partners for Mission Bio
missionbio@consortpartners.com
